Lynch Asset Management’s Novo Nordisk NVO Stock Holding History

Lynch Asset Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.97M	Sell	108,050 -300	-0.3%	-$14.2K	1.33%	24
2025 Q4	$5.51M	Sell	108,350 -350	-0.3%	-$17.9K	1.73%	14
2025 Q3	$6.03M	Hold	108,700	–	–	1.93%	12
2025 Q2	$7.5M	Buy	108,700 +600	+0.6%	+$40.8K	2.65%	11
2025 Q1	$7.51M	Buy	108,100 +1,150	+1%	+$95K	3.37%	7
2024 Q4	$9.2M	Buy	106,950 +650	+0.6%	+$70.3K	3.73%	5
2024 Q3	$12.7M	Buy	106,300 +1,500	+1%	+$200K	5.32%	2
2024 Q2	$15M	Sell	104,800 -2,000	-2%	-$265K	6.39%	2
2024 Q1	$13.7M	Hold	106,800	–	–	6.45%	2
2023 Q4	$11M	Hold	106,800	–	–	6.33%	2
2023 Q3	$9.71M	Hold	106,800	–	–	6.38%	2
2023 Q2	$8.64M	Hold	106,800	–	–	5.56%	2
2023 Q1	$8.5M	Hold	106,800	–	–	6.1%	2
2022 Q4	$7.23M	Hold	106,800	–	–	6.22%	3
2022 Q3	$5.32M	Hold	106,800	–	–	4.77%	6
2022 Q2	$5.95M	Hold	106,800	–	–	4.87%	6
2022 Q1	$5.93M	Hold	106,800	–	–	4.24%	7
2021 Q4	$5.98M	Buy	+106,800	New	+$5.79M	4.15%	7

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Lynch Asset Management's NVO Position: Q1 2026 in Review

Lynch Asset Management reduced its Novo Nordisk (NVO) stake by 0.28% in Q1 2026, selling an estimated $14.2K and leaving 108,050 shares worth $3.97M. The position accounts for 1.33% of the portfolio, ranked #24.

Lynch Asset Management first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $15M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Lynch Asset Management held 108,050 shares of Novo Nordisk worth $3.97M as of Q1 2026.
Lynch Asset Management sold 300 Novo Nordisk shares in Q1 2026, an estimated $14.2K.
Novo Nordisk made up 1.33% of Lynch Asset Management's portfolio in Q1 2026, its #24 holding.
Lynch Asset Management first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
Lynch Asset Management's Novo Nordisk position peaked at $15M in Q2 2024.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Lynch Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.